Fingerprint
Dive into the research topics where Ilan Bruchim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial
Ledermann, J. A., Lortholary, A., Penson, R. T., Asher, R., Gebski, V., Provencher, D., Bruchim, I., Huzarski, T., Barretina-Ginesta, M. P., Pipitone, S., Mileshkin, L., Colombo, N., Park-Simon, T. W., Matsumoto, K., Boere, I., Mikheeva, O., Kim, J. W., Girotto, G., Vergote, I. & Carter, D. & 2 others, , May 2026, In: International Journal of Gynecological Cancer. 36, 5, 104556.Research output: Contribution to journal › Article › peer-review
Open Access -
Precision medicine, insulin-like growth factors and cancer therapy
Werner, H. & Bruchim, I., 2025, In: Exploration of Medicine. 6, 1001342.Research output: Contribution to journal › Review article › peer-review
Open Access -
Revisiting the paradigm: Asymptomatic high-grade endometrial cancer diagnosis is not associated with improved outcomes
Namazov, A., Helpman, L., Eitan, R., Vaknin, Z., Lavie, O., Amit, A., Levy, T., Ben Shachar, I., Atlas, I., Bruchim, I., Ben Arie, A. & Gemer, O., Nov 2025, In: European Journal of Surgical Oncology. 51, 11, 110427.Research output: Contribution to journal › Article › peer-review
-
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers
Chator, C., Yanaihara, N., Chabaud, S., Parma, G. M., Dima, A. L., Clamp, A., Ferron, G., Kroep, J. R., Leary, A., Cibula, D., Fiteni, F., Bruchim, I., Serrier, H., Carroll, S., Belmont, A. S., Peron, J. & You, B., 1 Jan 2025, In: Therapeutic Advances in Medical Oncology. 17Research output: Contribution to journal › Article › peer-review
Open Access -
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Graybill, W. S., Vergote, I., Pothuri, B., Anttila, M., O’Malley, D. M., Lorusso, D., Haggerty, A. F., Fabbro, M., Chan, J. K., Heitz, F., Willmott, L. J., Bruchim, I., Zhuo, Y., Estévez-García, P., Monk, B. J., Denys, H., Knudsen, A., Tinker, A. V., Sánchez, L. M. & Provencher, D. & 4 others, , Jan 2025, In: Journal of Comparative Effectiveness Research. 14, 1, e240133.Research output: Contribution to journal › Article › peer-review
Open Access